We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Aerobic Exercise Training in Mild Cognitive Impairment Study (AETMCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01146717
Recruitment Status : Completed
First Posted : June 17, 2010
Last Update Posted : October 26, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:

This study is being done to find out whether regulation of brain blood flow is altered in patents with mild cognitive impairment (those who have memory problems but otherwise healthy) when compared with healthy elderly individuals. In addition, this study will determine whether exercise training improves brain blood flow, brain structure, and brain function in patients with mild cognitive impairment (MCI).

This is a research study because at present the investigators know little about brain blood flow regulation in patients with mild cognitive impairment. The investigators also know little about whether exercise training improves brain blood flow, brain structure, and brain function in patients with mild cognitive impairment.

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Behavioral: Exercise Behavioral: Balance training Phase 2

Detailed Description:

We plan to study 70 patients with amnestic MCI and 30 healthy older adults with similar age, sex, and educational level in this research at the University of Texas Southwestern(UTSW) Medical Center Dallas and Texas Health Presbyterian Hospital Dallas - Institute for Exercise an Environmental Medicine (IEEM).

To help decide if you qualify to be in this study, the researchers may ask you questions about your health, including medications you take and any surgical procedures you have had. You may also have to fill out certain forms or have the following exams, tests or procedures. The screening process usually takes 2-3 hours.

You will be required to come for 7-9 visits including the initial screening for eligibility to participate in this study. The experiments will measure your brain perfusion, vascular function and exercise capacity.

For the healthy controls, the expected length of this study will be about 2-3 months including all the test visits. Your participation in this study will end following completion of your testing.

For those with Mild Cognitive Impairment, the expected length of this study will be about 18 months including all the test visits and exercise training. Your participation in this study will end following completion of your repeat testing after one-year exercise training or control intervention. On occasion, training may be delayed due to injury, illness or personal matters. If this is the case, your enrollment in the study may last longer than one year as we attempt to complete the training and testing.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Mild Cognitive Impairment:Cerebrovascular Dysfunction and Exercise
Study Start Date : March 2010
Primary Completion Date : September 2016
Study Completion Date : September 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Exercise Behavioral: Exercise
Patients with mild cognitive impairment will undergo moderate intensity endurance exercise training for one year.
Placebo Comparator: Control group Behavioral: Balance training
A group of patients with mild cognitive impairment will perform flexibility and balance training for one year as a control group.

Outcome Measures

Primary Outcome Measures :
  1. Cognitive function [ Time Frame: One year ]
    A comprehensive battery of neuropsychological tests focused on memory and executive function will be used to assess effects of exercise on cognitive function.

Secondary Outcome Measures :
  1. Cerebrovascular function [ Time Frame: One year ]
    Transcranial Doppler and perfusion magnetic resonance imaging (MRI) will be used to measure cerebrovascular function/brain perfusion before and after exercise training.

  2. Brain tissue volume and white matter integrity [ Time Frame: One year ]
    Magnetic resonance imaging (MRI) will be used to measure changes in brain volume and white matter integrity before and after exercise training.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age 55-80 years old, Male or Female
  2. Control Subjects: absence of cognitive complaints and normal performance in Uniform Data Set (UDS) neuropsychological tests.
  3. For patients: Diagnosis of amnestic MCI (single and multiple domains) by Petersen's criteria (as modified for ADNI-GO study).
  4. Stable medical condition for > 6 months
  5. Sable medications for >2 months (use of cholinesterase inhibitors, or prior use of multivitamins is allowed)
  6. Caregiver/informant available to accompany patient for scheduled visits in case the patient develops cognitive impairment that interferes with independent study participation.
  7. Fluency of patient and caregiver in English
  8. Ability to return to clinic for additional visits over a 12 month period.
  9. ≥ 10 years of education or enough work history to exclude mental retardation.
  10. Adequate visual and auditory acuity to allow neuropsychological testing.
  11. Screening laboratory tests and ECG without significant abnormalities that might interfere with the study.
  12. Physical ability to undergo endurance exercise training.

Exclusion Criteria:

  1. Diagnosis of Alzheimer's Disease or other type of dementia.
  2. Participant enrolled in any other investigational drug study within 2 months or longer, depending on the investigational drug half-life.
  3. Modified Hachinski Score ≥ 4.
  4. Subject has history in the past 2 years of epileptic seizures, or DSM-IV criteria of any major psychiatric disorders.
  5. Past history or MRI evidence of brain damage including significant trauma, stroke, hydrocephalus, mental retardation or serious neurological disorder.
  6. Carotid stent or sever stenosis.
  7. Significant history of active alcoholism or drug abuse.
  8. History of myocardial infarction within the previous year. Unstable cardiac, renal, lung, liver or other severe chronic diseases.
  9. Uncontrolled hypertension (Systolic Blood Pressure (SBP) ≥160, Diastolic Blood Pressure (DBP) ≥100)or hypotension (SBP <100 mmHg).
  10. Currently diagnosed and being treated for Diabetes Mellitus (DM).
  11. Obesity with Body Mass Index (BMI) ≥ 35.
  12. History of familial early onset (<55 years old) dementia
  13. Pacemaker or other medical device of metal that precludes performing MRI.
  14. Subjects who have been engaged in moderate intensity aerobic exercise training for > 30 minutes, 3 times per week over the past 2 years.
  15. History of a clinical diagnosis of B12 deficiency or hypothyroidism. (stable treatment for at least 3 months is allowed).
  16. Chronic inflammatory diseases including, lupus, rheumatoid arthritis and polymyalgia rheumatica.

Prohibited Medications:

  • narcotics
  • anti-Parkinsonian medications
  • anti-convulsants for treatment of seizure disorder
  • drugs that can influence psychometric test results.

    • Subjects on a statins or non-steroidal anti-inflammatory drug (NSAID) are eligible but must be on a stable dose for at least 2 months.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01146717

United States, Texas
UT Southwestern ADC/Institute for Exercise and Environmental Medicine
Dallas, Texas, United States, 75231
Sponsors and Collaborators
University of Texas Southwestern Medical Center
National Institute on Aging (NIA)
Principal Investigator: Rong Zhang, PhD UTSW
More Information

Additional Information:
Responsible Party: Rong Zhang, Dr. Rong Zhang, UTSW, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT01146717     History of Changes
Other Study ID Numbers: 032009-065
R01AG033106-01A2 ( U.S. NIH Grant/Contract )
First Posted: June 17, 2010    Key Record Dates
Last Update Posted: October 26, 2016
Last Verified: October 2016

Keywords provided by Rong Zhang, University of Texas Southwestern Medical Center:
Mild Cognitive Impairment

Additional relevant MeSH terms:
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders